Patents by Inventor Michael R. Adams

Michael R. Adams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5994337
    Abstract: The present invention relates to a method of using 17.alpha.-dihydroequilenin and metabolic conjugates thereof to prevent and reduce atherogenesis in males and females without causing endometrial proliferation in females and without producing feminizing changes in males. 17.alpha.-dihydroequilenin was evaluated for its effects on plasma lipid and lipoprotein, glucose, insulin concentrations, coronary artery vasomotor function, and reproductive organ and mammary gland proliferation in atherosclerotic mammals. 17.alpha.-dihydroequilenin was found to prevent endothelium-dependent vasoconstriction in males (p<0.05) and ovariectomized females (p<0.08). 17.alpha.-dihydroequilenin treatment increased plasma apolipoprotein A-l concentrations (p<0.05) and lowered fasting insulin concentrations (p<0.05) without changing fasting plasma glucose concentrations in males. 17.alpha.-dihydroequilenin had no other effects on plasma lipid and lipoprotein concentrations in either males or females. Also, 17.alpha.
    Type: Grant
    Filed: January 12, 1998
    Date of Patent: November 30, 1999
    Assignees: Wake Forest University, American Home Products Corporation
    Inventors: Scott A. Washburn, Thomas B. Clarkson, Michael R. Adams, Thomas C. Register, J. Koudy Williams, Janice D. Wagner, J. Mark Cline, Steven J. Adelman
  • Patent number: 5952374
    Abstract: Methods for inhibiting the development and relieving the symptoms of Alzheimer's disease and related dementias are provided. A phytoestrogenic isoflavone compound is administered to a human predisposed to developing Alzheimer's disease or a related dementia, or having Alzheimer's disease or a related dementia, in an amount effective to inhibit the development or relieve the symptoms of the disease. The phytoestrogenic isoflavone compound is selected from at least one of genistein, genistin, 6'-OMal genistin, 6'-OAc genistin, daidzein, daidzin, 6'-OMal daidzin, 6'-OAc daidzin, glycitein, glycitin, 6'-OMal glycitin, or mixtures thereof. The phytoestrogenic isoflavone compound is effective to up-regulate choline acetyltransferase mRNA and nerve growth factor mRNA.
    Type: Grant
    Filed: September 29, 1997
    Date of Patent: September 14, 1999
    Assignee: Protein Technologies International, Inc.
    Inventors: Thomas Boston Clarkson, Jr., Mary Susan Anthony, Yuanlong Pan, Michael R. Adams, Doyle H. Waggle